Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura following Endovascular Treatment of Spontaneous Carotid Artery Dissection

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening multisystem disease secondary to platelet aggregation. We present a patient who developed profound thrombocytopenia and anemia 8 days following initiation of therapy with clopidogrel after stent placement for carotid artery dissection. She did not have a disintegrin and metalloproteinase with thrombospondin domain 13 (ADAMTS 13) deficiency. Management included steroids and therapeutic plasma exchange. Clopidogrel has rarely been associated with TTP. Unlike other causes of acquired TTP, the diagnosis of early clopidogrel-associated TTP is largely clinical given the infrequent reduction in ADAMTS 13 activity.

Keywords

clopidogrel - TTP - carotid - stent - thrombocytopenia

• References

• 1 Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev 1993; 7 (2) 94-103
• 2 George J, Leung L, Timauer J. Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults. Available at: http://www.uptodate.com.proxy.library.stonybrook.edu/contents/diagnosis-of-thrombotic-thrombocytopenic-purpura-hemolytic-uremic-syndrome-in-adults?source=search_result&search=ttp+diagnosis&selectedTitle=1~150 . Accessed May 27, 2015
• 3 Scully M, Hunt BJ, Benjamin S , et al; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158 (3) 323-335
• 4 Bennett CL, Connors JM, Carwile JM , et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342 (24) 1773-1777
• 5 Verbij FC, Fijnheer R, Voorberg J, Sorvillo N. Acquired TTP: ADAMTS13 meets the immune system. Blood Rev 2014; 28 (6) 227-234
• 6 Zakarija A, Kwaan HC, Moake JL , et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008). Kidney Int Suppl 2009; (112) S20-S24
• 7 Ricotta JJ, Aburahma A, Ascher E, Eskandari M, Faries P, Lal BK ; Society for Vascular Surgery. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. J Vasc Surg 2011; 54 (3) e1-e31
• 8 Liapis CD, Bell PR, Mikhailidis D , et al; ESVS Guidelines Collaborators. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009; 37 (4, Suppl): 1-19
• 9 Bell B, Layland J, Poon K, Spaulding C, Walters D. Focused clinical review: periprocedural management of antiplatelet therapy in patients with coronary stents. Heart Lung Circ 2011; 20 (7) 438-445
• 10 Jacob S, Dunn BL, Qureshi ZP , et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38 (8) 845-853
• 11 Bennett CL, Kim B, Zakarija A , et al; SERF-TTP Research Group. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007; 50 (12) 1138-1143
• 12 Matetzky S, Fefer P, Shenkman B, Varon D, Savion N, Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol 2008; 102 (5) 524-529
• 13 Tan LA, Keigher KM, Munich SA, Moftakhar R, Lopes DK. Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointerv Surg 2015; 7 (3) 217-221
• 14 Price MJ, Angiolillo DJ, Teirstein PS , et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124 (10) 1132-1137